These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 18574923)

  • 1. The use of disease-modifying agents in multiple sclerosis--by the Canadian Network of MS Clinics.
    O'Connor P; Devonshire V;
    Can J Neurol Sci; 2008 May; 35(2):127-32. PubMed ID: 18574923
    [No Abstract]   [Full Text] [Related]  

  • 2. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
    Oger J; Freedman M
    Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
    [No Abstract]   [Full Text] [Related]  

  • 4. [Aspects of early MS treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2010 Jul; 33(7):233. PubMed ID: 20687459
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of multiple sclerosis--now and in future. The Danish Multiple Sclerosis Society and the Danish Multiple Sclerosis Group].
    Sellebjerg FT; Sørensen PS;
    Ugeskr Laeger; 2007 Mar; 169(12):1121. PubMed ID: 17394832
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple sclerosis.
    Cuddy ML
    J Pract Nurs; 2007; 57(2):5-6, 12; quiz 13-4. PubMed ID: 17941188
    [No Abstract]   [Full Text] [Related]  

  • 7. Translating new insights into treatment optimisation in multiple sclerosis.
    Fazekas F; Kieseier BC
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S1-2. PubMed ID: 19200857
    [No Abstract]   [Full Text] [Related]  

  • 8. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
    Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
    Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of MS symptoms. Here also are guidelines necessary].
    Henze T; Toyka KV
    Nervenarzt; 2004 Aug; 75 Suppl 1():S1. PubMed ID: 15480525
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching therapies in MS: what are the options?
    Markowitz CE
    J Clin Psychiatry; 2015 Feb; 76(2):e6. PubMed ID: 25742221
    [No Abstract]   [Full Text] [Related]  

  • 11. Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.
    Vidal-Jordana A; Montalban X
    Neuroimaging Clin N Am; 2017 May; 27(2):195-204. PubMed ID: 28391781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of multiple sclerosis treatment.
    Cohen JA
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.
    Hartung HP; Kieseier BC
    Curr Opin Neurol; 2014 Jun; 27(3):243-5. PubMed ID: 24751962
    [No Abstract]   [Full Text] [Related]  

  • 14. Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients?
    Kingwell E; Tremlett H
    Expert Rev Neurother; 2009 Sep; 9(9):1263-5. PubMed ID: 19769440
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple sclerosis: new insights in pathogenesis and novel therapeutics.
    Ontaneda D; Hyland M; Cohen JA
    Annu Rev Med; 2012; 63():389-404. PubMed ID: 21888515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modifying therapies in multiple sclerosis.
    Sharrack B; Jenkins T
    Int J Clin Pract; 2010 Apr; 64(5):532-4. PubMed ID: 20456205
    [No Abstract]   [Full Text] [Related]  

  • 17. [Symptomatic therapy of multiple sclerosis].
    Henze T
    Nervenarzt; 2004 Aug; 75 Suppl 1():2-39. PubMed ID: 15480526
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial.
    Thouvenot É; de Seze J
    Rev Neurol (Paris); 2019 Jun; 175(6):339-340. PubMed ID: 31088691
    [No Abstract]   [Full Text] [Related]  

  • 19. Multiple sclerosis treatment: current best practice.
    Niino M
    Expert Rev Clin Immunol; 2012 Aug; 8(6):505-7. PubMed ID: 22992142
    [No Abstract]   [Full Text] [Related]  

  • 20. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.